Could a custom vaccine beat kidney cancer?

NCT ID NCT00625755

Completed Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a personalized vaccine made from a patient's own tumor cells mixed with immune cells from a healthy donor. The goal was to see if the vaccine is safe and can help the immune system attack advanced kidney cancer. Forty people with stage IV kidney cancer took part. The vaccine was given as a series of injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized fusion-cell vaccine made from the patient's own tumor cells and another person's immune cells
What this could lead to: If it works, this could point toward a new way to train the immune system to fight advanced kidney cancer without needing lifelong medication.
What could go wrong: This is an early-phase trial with only 40 people, so it may not work for everyone. The vaccine is personalized and complex, and side effects or lack of immune response are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

BIDMC

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.